

## Zamerovimab

Cat. No.:	HY-P99513
CAS No.:	2419087-87-7
Target:	RABV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Zamerovimab (CTB011; SYN023) is a mixture of human monoclonal antibodies consisting of CTB011 and CTB012. Zamerovimab binds to non-overlapping epitopes on rabies virus (RABV) glycoprotein, where CTB011 binds to antigenic site III. Zamerovimab can be used in rabies studies <sup>[1]</sup> .
<b>In Vitro</b>	Zamerovimab (CTB011; SYN023) (0.001-100 µg/mL, 4 h) can induce cytotoxicity and promote viral clearance in a dose-dependent manner in CVS-infected BSR cells, also suggesting that cytotoxicity is associated with the specificity of cells expressing G proteins that are targeted by CTB011 <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Zamerovimab (CTB011; SYN023) (0.03-1.0 mg/kg, right gastrocnemius injection, once, 35 days) can increase the survival of Syrian hamsters infected with RABV BD06 virus in a dose-dependent manner, with survival rates of 58%, 83%, 100% and 100% at doses of 0.03, 0.1, 0.3 and 1.0 mg/kg, respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Tzu-Yuan Chao, et al. SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies. PLoS Negl Trop Dis. 2017 Dec 20;11(12):e0006133.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA